Recombinant Vector Vaccine Development for COVID-19

by JoannaBowie
Published: July 27, 2022 (2 weeks ago)
Category
Expires
August 24, 2022

The emergence and outbreak of emerging infectious diseases is a global challenge to public health. At present, scientists from academia and biopharmaceutical industries around the world are working hard to find ways to prevent and treat coronavirus infections. Creative Biostructure has rapidly integrated related businesses characterized by structural biology and currently provides preclinical development services for recombinant vector vaccines to meet the urgent needs of SARS-CoV-2 vaccine R&D.

Recombinant Vector Vaccine Development for COVID-19